[go: up one dir, main page]

MX2008009992A - Composiciones que contienen bisfosfonato y un antifolato. - Google Patents

Composiciones que contienen bisfosfonato y un antifolato.

Info

Publication number
MX2008009992A
MX2008009992A MX2008009992A MX2008009992A MX2008009992A MX 2008009992 A MX2008009992 A MX 2008009992A MX 2008009992 A MX2008009992 A MX 2008009992A MX 2008009992 A MX2008009992 A MX 2008009992A MX 2008009992 A MX2008009992 A MX 2008009992A
Authority
MX
Mexico
Prior art keywords
compositions
antifolate
bisphosphonate
arthritis
osteoarthritis
Prior art date
Application number
MX2008009992A
Other languages
English (en)
Inventor
Michael J Walsh
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of MX2008009992A publication Critical patent/MX2008009992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para el tratamiento de la artritis, en particular de la artritis reumatoide y osteoartritis. Esas composiciones incluyen cuando menos un antifolato y cuando menos un bisfosfonato, o sus sales farmacéuticamente aceptables.
MX2008009992A 2006-02-06 2007-02-02 Composiciones que contienen bisfosfonato y un antifolato. MX2008009992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77117406P 2006-02-06 2006-02-06
PCT/US2007/002941 WO2007092338A2 (en) 2006-02-06 2007-02-02 Compositions comprising a bisphosphonate and an antifolate

Publications (1)

Publication Number Publication Date
MX2008009992A true MX2008009992A (es) 2008-10-17

Family

ID=38345692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009992A MX2008009992A (es) 2006-02-06 2007-02-02 Composiciones que contienen bisfosfonato y un antifolato.

Country Status (9)

Country Link
US (1) US20070225258A1 (es)
EP (1) EP1988907A4 (es)
JP (1) JP2009525976A (es)
CN (1) CN101405007A (es)
AU (1) AU2007212508A1 (es)
BR (1) BRPI0707516A2 (es)
CA (1) CA2641456A1 (es)
MX (1) MX2008009992A (es)
WO (1) WO2007092338A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064465A1 (en) * 2007-11-16 2009-05-22 Mucosal Therapeutics Methods for treating and preventing bisphosphonate-induced osteonecrosis
US20100260825A1 (en) * 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN103501819B (zh) 2011-02-24 2016-08-17 Ktb肿瘤研究有限责任公司 二膦酸盐-前药
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
MY191481A (en) * 2014-10-15 2022-06-28 Abiogen Pharma Spa Use of neridronic acid or of its salt for the treatment of osteoarthrosis
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN107312038B (zh) * 2017-06-29 2019-02-19 扬州大学 甲氨蝶呤与阿伦磷酸钠偶联物的制备方法
CN107200753B (zh) * 2017-06-29 2019-02-19 扬州大学 一种甲氨蝶呤与阿伦磷酸钠偶联物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2119794C1 (ru) * 1992-06-30 1998-10-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Использование фосфонатов и нестероидных противовоспалительных лекарственных средств для лечения артрита, способ лечения
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
AU2003280373A1 (en) * 2002-10-15 2004-05-04 Novartis Ag Method of administering bisphosphonates

Also Published As

Publication number Publication date
WO2007092338A3 (en) 2007-12-06
BRPI0707516A2 (pt) 2011-05-10
WO2007092338A2 (en) 2007-08-16
US20070225258A1 (en) 2007-09-27
JP2009525976A (ja) 2009-07-16
CA2641456A1 (en) 2007-08-16
AU2007212508A1 (en) 2007-08-16
EP1988907A2 (en) 2008-11-12
EP1988907A4 (en) 2010-04-14
CN101405007A (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
MX2008009992A (es) Composiciones que contienen bisfosfonato y un antifolato.
WO2007098353A3 (en) Bioerodible endoprostheses and methods of making the same
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
MX2009002584A (es) Ferula de anclaje pelvico.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
HK1203805A1 (en) Patient-adapted posterior stabilized knee implants, designs and related methods and tools
EP2005569A4 (en) Energy generating systems for implanted medical devices
TNSN08191A1 (en) Kinase inhibitors
WO2008034013A3 (en) Medical devices and methods of making the same
AU2013207611A1 (en) Surgical implants, tools, and methods for treating pelvic conditions
PL2086642T3 (pl) DNaza do leczenia męskiej subpłodności
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200738725A (en) Unsaturated mTOR inhibitors
AU2005228817A1 (en) Remedy or preventive for arthritis
UA97502C2 (ru) Кристаллическая твердая основа разагилина
WO2007062188A3 (en) Activin-actriia antagonists and uses for promoting bone growth
TN2010000269A1 (en) 4-phenylpyrane-3,5-diones, 4-phenylthiopyrane-3,5-diones and 2- phenylcyclohexane -1,3,5 - triones as herbicides
AU2013207605A1 (en) Posterior stabilized knee prosthesis
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2007126883A3 (en) Surveying sterilizer methods and systems
WO2008046642A3 (en) Coated implant
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2008062282A3 (en) An improved process for the synthesis of solifenacin
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal